We are live on
!
Find out more
EP
Eversept Partners Portfolio holdings
AUM
$1.93B
Turnover
41.06%
1-Year Est. Return
160.8%
This Fund
S&P 500
This Quarter
Est. Return
+71.22%
1 Year Est. Return
+160.8%
3 Year Est. Return
+321.09%
5 Year Est. Return
+420.29%
10 Year Est. Return
–
AUM
$729M
AUM Growth
+$327M
(+81%)
Cap. Flow
+$45.1M
Cap. Flow
% of AUM
6.18%
Top 10 Holdings %
Top 10 Hldgs %
57.09%
Holding
84
New
23
Increased
22
Reduced
20
Closed
15
Avg Time Held Equity + Options
0.8
years
Top 10 Avg Time Held Equity + Options
0.4
years
Top 20 Avg Time Held Equity + Options
0.8
years
Avg Time Held Equity only
0.8
years
Top 10 Avg Time Held Equity only
0.4
years
Top 20 Avg Time Held Equity only
0.8
years
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
HZNP
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
|
+$40.8M |
| 2 |
United Therapeutics
UTHR
|
+$26.2M |
| 3 |
HSKA
Heska Corp
HSKA
|
+$20M |
| 4 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
+$18.2M |
| 5 |
AstraZeneca
AZN
|
+$10.8M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
ChemoCentryx, Inc.
CCXI
|
+$29.3M |
| 2 |
ZGNX
Zogenix, Inc.
ZGNX
|
+$27.8M |
| 3 |
Danaher
DHR
|
+$20.4M |
| 4 |
Apellis Pharmaceuticals
APLS
|
+$15.4M |
| 5 |
GSK
GSK
|
+$11.6M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 81.4% |
| 2 | Miscellaneous | 16.98% |
| 3 | Communication Services | 1.62% |
| 4 | Financials | 0% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | Held Since | |
|---|---|---|---|---|---|---|---|
76
MacroGenics
MGNX
$207M
| – | – |
-91,998
| Closed | -$535K | – |
|
77
Envista
NVST
$3.68B
| – | – |
-109,212
| Closed | -$1.63M | – |
|
78
Puma Biotechnology
PBYI
$508M
| – | – |
-58,251
| Closed | -$492K | – |
|
79
Xenon Pharmaceuticals
XENE
$3.25B
| – | – |
-71,591
| Closed | -$812K | – |
|
|
AGRX
80
DELISTED
Agile Therapeutics
AGRX
| – | – |
-356
| Closed | -$1.32M | – |
|
|
XLRN
81
DELISTED
Acceleron Pharma
XLRN
| – | – |
-42,305
| Closed | -$3.8M | – |
|
|
KDMN
82
DELISTED
Kadmon Holdings, Inc.
KDMN
| – | – |
-975,350
| Closed | -$4.09M | – |
|
|
GNMK
83
DELISTED
GenMark Diagnostics, Inc
GNMK
| – | – |
-524,257
| Closed | -$2.16M | – |
|
|
PFNX
84
DELISTED
Pfenex Inc.
PFNX
| – | – |
-46,293
| Closed | -$408K | – |
|
Similar funds
SWM
RIA
SI
SG
DCP
SI
MFM
FWP
Eversept Partners's Q2 2020 Portfolio in Review
As of Q2 2020, Eversept Partners held 84 positions worth $729M, up 81% from $402M the previous quarter. Its ten largest holdings account for 57% of the portfolio.
Eversept Partners deployed $45.1M of net new capital in Q2 2020, opening 23 new positions and adding to 22 existing holdings. Its largest new stake was Horizon Therapeutics Public Limited Company Ordinary Shares: 954,738 shares worth $53.1M.
By sector, the portfolio is most concentrated in Healthcare at 81% of assets, down from 92% a quarter earlier, followed by Miscellaneous and Communication Services.
On the sell side, the largest reduction was ChemoCentryx, Inc., an estimated $29.3M trimmed.
- Eversept Partners's largest Q2 2020 buy was Horizon Therapeutics Public Limited Company Ordinary Shares: 954,738 shares worth $53.1M.
- Eversept Partners added most to Heska Corp in Q2 2020, an estimated $20M increase.
- Eversept Partners's biggest Q2 2020 reduction was ChemoCentryx, Inc., cutting an estimated $29.3M.
- Eversept Partners fully exited Kadmon Holdings, Inc. in Q2 2020, selling an estimated $4.09M.
- Eversept Partners's ten largest holdings make up 57% of its $729M portfolio in Q2 2020.
- Eversept Partners opened 23 new positions and closed 15 in Q2 2020.
- Eversept Partners's portfolio value rose 81% quarter-over-quarter to $729M.
Based on Eversept Partners's 13F filing for Q2 2020, filed 13 Aug 2020.